oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls
Dept of Pharmacology and Clinical Neuroscience, Neurology, Umeå University, Umeå, Sweden.
Unit of Research, Education and Development, Östersund Hospital, Region Jaämtland Härjedalen, Östersund, Sweden.
Dept of Pharmacology and Clinical Neuroscience, Neurology, Umeå University, Umeå, Sweden.
Dept of Pharmacology and Clinical Neuroscience, Neurology, Umeå University, Umeå, Sweden.
Vise andre og tillknytning
2018 (engelsk)Inngår i: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 13, nr 2, artikkel-id e0192516Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective: To investigate changes in the cerebrospinal fluid (CSF) immunological profile after treatment switch from first-line injectables to rituximab in patients with relapsing-remitting MS (RRMS), and to compare the profile in MS patients with healthy controls (HC).

Method: Cerebrospinal fluid from 70 patients with clinically stable RRMS and 55 HC was analysed by a multiplex electrochemiluminescence method for a broad panel of cytokines and immunoactive substances before, and over a two-year period after, treatment switch to rituximab. After quality assessment of data, using a predefined algorithm, 14 analytes were included in the final analysis.

Results: Ten of the 14 analytes differed significantly in MS patients compared with HC at baseline. Levels of IP-10 (CXCL10), IL-12/23p40, IL-6, sVCAM1, IL-15, sICAM1 and IL-8 (CXCL8) decreased significantly after treatment switch to rituximab. The cytokines IP-10 and IL-12/IL-23p40 displayed the largest difference versus HC at baseline and also the largest relative reduction after therapy switch to rituximab.

Conclusion: We found significant changes in the immunological profile after therapy switch to rituximab in RRMS in the direction towards the values of HC. IP-10 and IL12/IL-23p40 deserve further studies as part of the immunopathogenesis of MS as well as for the mode of action of rituximab in MS.

sted, utgiver, år, opplag, sider
Public Library of Science , 2018. Vol. 13, nr 2, artikkel-id e0192516
HSV kategori
Identifikatorer
URN: urn:nbn:se:oru:diva-65640DOI: 10.1371/journal.pone.0192516ISI: 000424517900086Scopus ID: 2-s2.0-85041734965OAI: oai:DiVA.org:oru-65640DiVA, id: diva2:1189584
Merknad

Funding Agencies:

County Councils of Västerbotten, Jämtland/Härjedalen and Örebro  

Unit of Research, Education and Development, Region Jämtland Härjedalen  JLL-379731  JLL-649011  JLL 467731 

Syskonen Perssons Donationsfond  JLL-467381  JLL-652541 

Tilgjengelig fra: 2018-03-12 Laget: 2018-03-12 Sist oppdatert: 2018-08-20bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstScopus

Personposter BETA

Gunnarsson, Martin

Søk i DiVA

Av forfatter/redaktør
Gunnarsson, Martin
Av organisasjonen
I samme tidsskrift
PLoS ONE

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 17 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf